Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Invitrogen

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Originally published in Science Express on 22 June 2006
Science 21 July 2006:
Vol. 313. no. 5785, pp. 324 - 328
DOI: 10.1126/science.1129462
Prev | Table of Contents | Next

Research Articles

{alpha}-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models

Antony A. Cooper,1*{dagger} Aaron D. Gitler,2* Anil Cashikar,2{ddagger} Cole M. Haynes,1§ Kathryn J. Hill,1{dagger} Bhupinder Bhullar,2,3 Kangning Liu,4,5 Kexiang Xu,4 Katherine E. Strathearn,6 Fang Liu,6 Songsong Cao,7 Kim A. Caldwell,7 Guy A. Caldwell,7 Gerald Marsischky,3 Richard D. Kolodner,8 Joshua LaBaer,3 Jean-Christophe Rochet,6 Nancy M. Bonini,4,5 Susan Lindquist2,9||

Alpha-synuclein ({alpha}Syn) misfolding is associated with several devastating neurodegenerative disorders, including Parkinson's disease (PD). In yeast cells and in neurons {alpha}Syn accumulation is cytotoxic, but little is known about its normal function or pathobiology. The earliest defect following {alpha}Syn expression in yeast was a block in endoplasmic reticulum (ER)–to–Golgi vesicular trafficking. In a genomewide screen, the largest class of toxicity modifiers were proteins functioning at this same step, including the Rab guanosine triphosphatase Ypt1p, which associated with cytoplasmic {alpha}Syn inclusions. Elevated expression of Rab1, the mammalian YPT1 homolog, protected against {alpha}Syn-induced dopaminergic neuron loss in animal models of PD. Thus, synucleinopathies may result from disruptions in basic cellular functions that interface with the unique biology of particular neurons to make them especially vulnerable.

1 School of Biological Sciences, University of Missouri–Kansas City, Kansas City, MO 64110, USA.
2 Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
3 Harvard Institute of Proteomics, 320 Charles Street, Cambridge, MA 02141, USA.
4 Department of Biology, University of Pennsylvania, Philadelphia, PA 19104, USA.
5 Howard Hughes Medical Institute, Philadelphia, PA 19104, USA.
6 Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907–2091, USA.
7 Department of Biological Sciences, University of Alabama, Tuscaloosa, AL 35487, USA.
8 Ludwig Institute for Cancer Research, University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA.
9 Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.

* These authors contributed equally to this work.

{dagger} Present address: Garvan Institute of Medical Research, Sydney, Australia.

{ddagger} Present address: Medical College of Georgia, Augusta, GA, USA.

§ Present address: New York University, New York, NY, USA.

|| To whom correspondence should be addressed. E-mail: lindquist_admin{at}wi.mit.edu

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Traversing a wormhole to combat Parkinson's disease.
G. A. Caldwell and K. A. Caldwell (2008)
Disease Models and Mechanisms 1, 32-36
   Abstract »    Full Text »    PDF »
The fold of {alpha}-synuclein fibrils.
M. Vilar, H.-T. Chou, T. Luhrs, S. K. Maji, D. Riek-Loher, R. Verel, G. Manning, H. Stahlberg, and R. Riek (2008)
PNAS 105, 8637-8642
   Abstract »    Full Text »    PDF »
Phosphorylation at Ser-129 but Not the Phosphomimics S129E/D Inhibits the Fibrillation of {alpha}-Synuclein.
K. E. Paleologou, A. W. Schmid, C. C. Rospigliosi, H.-Y. Kim, G. R. Lamberto, R. A. Fredenburg, P. T. Lansbury Jr., C. O. Fernandez, D. Eliezer, M. Zweckstetter, et al. (2008)
J. Biol. Chem. 283, 16895-16905
   Abstract »    Full Text »    PDF »
Chaperone-dependent amyloid assembly protects cells from prion toxicity.
P. M. Douglas, S. Treusch, H.-Y. Ren, R. Halfmann, M. L. Duennwald, S. Lindquist, and D. M. Cyr (2008)
PNAS 105, 7206-7211
   Abstract »    Full Text »    PDF »
Transgenic Mice Overexpressing Tyrosine-to-Cysteine Mutant Human {alpha}-Synuclein: A PROGRESSIVE NEURODEGENERATIVE MODEL OF DIFFUSE LEWY BODY DISEASE.
W. Zhou, J. B. Milder, and C. R. Freed (2008)
J. Biol. Chem. 283, 9863-9870
   Abstract »    Full Text »    PDF »
Functional Mitochondria Are Required for {alpha}-Synuclein Toxicity in Aging Yeast.
S. Buttner, A. Bitto, J. Ring, M. Augsten, P. Zabrocki, T. Eisenberg, H. Jungwirth, S. Hutter, D. Carmona-Gutierrez, G. Kroemer, et al. (2008)
J. Biol. Chem. 283, 7554-7560
   Abstract »    Full Text »    PDF »
The 2008 Genetics Society of America Medal.
N. Hopkins (2008)
Genetics 178, 1125-1128
   Full Text »    PDF »
{alpha}-Synuclein-induced Aggregation of Cytoplasmic Vesicles in Saccharomyces cerevisiae.
J. H. Soper, S. Roy, A. Stieber, E. Lee, R. B. Wilson, J. Q. Trojanowski, C. G. Burd, and V. M.-Y. Lee (2008)
Mol. Biol. Cell 19, 1093-1103
   Abstract »    Full Text »    PDF »
The phosphorylation state of Ser-129 in human {alpha}-synuclein determines neurodegeneration in a rat model of Parkinson disease.
O. S. Gorbatyuk, S. Li, L. F. Sullivan, W. Chen, G. Kondrikova, F. P. Manfredsson, R. J. Mandel, and N. Muzyczka (2008)
PNAS 105, 763-768
   Abstract »    Full Text »    PDF »
Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model.
S. Hamamichi, R. N. Rivas, A. L. Knight, S. Cao, K. A. Caldwell, and G. A. Caldwell (2008)
PNAS 105, 728-733
   Abstract »    Full Text »    PDF »
Unregulated Cytosolic Dopamine Causes Neurodegeneration Associated with Oxidative Stress in Mice.
L. Chen, Y. Ding, B. Cagniard, A. D. Van Laar, A. Mortimer, W. Chi, T. G. Hastings, U. J. Kang, and X. Zhuang (2008)
J. Neurosci. 28, 425-433
   Abstract »    Full Text »    PDF »
Induction of the Phase II Detoxification Pathway Suppresses Neuron Loss in Drosophila Models of Parkinson's Disease.
K. Trinh, K. Moore, P. D. Wes, P. J. Muchowski, J. Dey, L. Andrews, and L. J. Pallanck (2008)
J. Neurosci. 28, 465-472
   Abstract »    Full Text »    PDF »
The Parkinson's disease protein {alpha}-synuclein disrupts cellular Rab homeostasis.
A. D. Gitler, B. J. Bevis, J. Shorter, K. E. Strathearn, S. Hamamichi, L. J. Su, K. A. Caldwell, G. A. Caldwell, J.-C. Rochet, J. M. McCaffery, et al. (2008)
PNAS 105, 145-150
   Abstract »    Full Text »    PDF »
Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers.
K. Sakamoto, T. Honda, S. Yokoya, S. Waguri, and J. Kimura (2007)
FASEB J 21, 4087-4094
   Abstract »    Full Text »    PDF »
Polyunsaturated Fatty Acids Induce {alpha}-Synuclein-Related Pathogenic Changes in Neuronal Cells.
K. Assayag, E. Yakunin, V. Loeb, D. J. Selkoe, and R. Sharon (2007)
Am. J. Pathol. 171, 2000-2011
   Abstract »    Full Text »    PDF »
Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder.
C. Klein and M. G. Schlossmacher (2007)
Neurology 69, 2093-2104
   Abstract »    Full Text »    PDF »
Methionine Sulfoxide Reductase A and a Dietary Supplement S-Methyl-L-Cysteine Prevent Parkinson's-Like Symptoms.
R. Wassef, R. Haenold, A. Hansel, N. Brot, S. H. Heinemann, and T. Hoshi (2007)
J. Neurosci. 27, 12808-12816
   Abstract »    Full Text »    PDF »
Beating a dead horse: Dopamine and Parkinson disease.
J. E. Ahlskog (2007)
Neurology 69, 1701-1711
   Abstract »    Full Text »    PDF »
Parkinson's disease.
B. Thomas and M. F. Beal (2007)
Hum. Mol. Genet. 16, R183-R194
   Abstract »    Full Text »    PDF »
In and Out of the ER: Protein Folding, Quality Control, Degradation, and Related Human Diseases.
D. N. Hebert and M. Molinari (2007)
Physiol Rev 87, 1377-1408
   Abstract »    Full Text »    PDF »
Analysis of GTPase-activating proteins: Rab1 and Rab43 are key Rabs required to maintain a functional Golgi complex in human cells.
A. K. Haas, S.-i. Yoshimura, D. J. Stephens, C. Preisinger, E. Fuchs, and F. A. Barr (2007)
J. Cell Sci. 120, 2997-3010
   Abstract »    Full Text »    PDF »
YGR198w (YPP1) targets A30P {alpha}-synuclein to the vacuole for degradation.
T. R. Flower, C. Clark-Dixon, C. Metoyer, H. Yang, R. Shi, Z. Zhang, and S. N. Witt (2007)
J. Cell Biol. 177, 1091-1104
   Abstract »    Full Text »    PDF »
Pulmonary arterial hypertension: a disease of tethers, SNAREs and SNAPs?.
P. B. Sehgal and S. Mukhopadhyay (2007)
Am J Physiol Heart Circ Physiol 293, H77-H85
   Abstract »    Full Text »    PDF »
A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases.
W. Mandemakers, V. A. Morais, and B. De Strooper (2007)
J. Cell Sci. 120, 1707-1716
   Abstract »    Full Text »    PDF »
Prime Time for {alpha}-Synuclein.
A. D. Gitler and J. Shorter (2007)
J. Neurosci. 27, 2433-2434
   Full Text »    PDF »
Interaction of Genetic and Environmental Factors in a Drosophila Parkinsonism Model.
A. Chaudhuri, K. Bowling, C. Funderburk, H. Lawal, A. Inamdar, Z. Wang, and J. M. O'Donnell (2007)
J. Neurosci. 27, 2457-2467
   Abstract »    Full Text »    PDF »
Aberrant cytoplasmic sequestration of eNOS in endothelial cells after monocrotaline, hypoxia, and senescence: live-cell caveolar and cytoplasmic NO imaging.
S. Mukhopadhyay, F. Xu, and P. B. Sehgal (2007)
Am J Physiol Heart Circ Physiol 292, H1373-H1389
   Abstract »    Full Text »    PDF »
A New Evolutionary Paradigm for the Parkinson Disease Gene DJ-1.
J. I. Lucas and I. Marin (2007)
Mol. Biol. Evol. 24, 551-561
   Abstract »    Full Text »    PDF »
{alpha}-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity.
E. Kontopoulos, J. D. Parvin, and M. B. Feany (2006)
Hum. Mol. Genet. 15, 3012-3023
   Abstract »    Full Text »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)